-
EP2792357
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2792357
| EP2792357 - THROMBOEMBOLISM PREVENTIVE/THERAPEUTIC AGENT FOR THROMBOEMBOLISM PATIENTS HAVING SEVERE RENAL DYSFUNCTION [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 03.11.2017 Database last updated on 14.11.2024 | |
| Former | Request for examination was made Status updated on 27.07.2017 | Most recent event Tooltip | 03.11.2017 | Application deemed to be withdrawn | published on 06.12.2017 [2017/49] | Applicant(s) | For all designated states Daiichi Sankyo Company, Limited 3-5-1, Nihonbashi Honcho Chuo-ku Tokyo 103-8426 / JP | [2014/43] | Inventor(s) | 01 /
KIMURA, Tetsuya c/o DAIICHI SANKYO COMPANY LIMITED 1-2-58 Hiromachi Shinagawa-ku Tokyo 140-8710 / JP | 02 /
KUMAKURA, Tomohiko c/o DAIICHI SANKYO COMPANY LIMITED 1-2-58 Hiromachi Shinagawa-ku Tokyo 140-8710 / JP | 03 /
TACHIBANA, Masaya c/o DAIICHI SANKYO COMPANY LIMITED 1-2-58 Hiromachi Shinagawa-ku Tokyo 140-8710 / JP | 04 /
MATSUMOTO, Chiaki c/o DAIICHI SANKYO COMPANY LIMITED 1-2-58 Hiromachi Shinagawa-ku Tokyo 140-8710 / JP | 05 /
ABE, Kenji c/o DAIICHI SANKYO COMPANY LIMITED 1-2-58 Hiromachi Shinagawa-ku Tokyo 140-8710 / JP | [2014/43] | Representative(s) | Nieuwenhuys, William Francis Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [N/P] |
| Former [2014/43] | Nieuwenhuys, William Francis Marks & Clerk LLP 90 Long Acre London WC2E 9RA / GB | Application number, filing date | 12857962.0 | 13.12.2012 | WO2012JP82279 | Priority number, date | JP20110273516 | 14.12.2011 Original published format: JP 2011273516 | [2014/43] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013089164 | Date: | 20.06.2013 | Language: | JA | [2013/25] | Type: | A1 Application with search report | No.: | EP2792357 | Date: | 22.10.2014 | Language: | EN | [2014/43] | Search report(s) | International search report - published on: | JP | 20.06.2013 | (Supplementary) European search report - dispatched on: | EP | 20.04.2015 | Classification | IPC: | A61K31/4439, A61P7/02, A61P9/10, A61P13/12 | [2014/43] | CPC: |
A61K31/444 (EP,US);
A61P13/12 (EP);
A61P7/02 (EP);
A61P9/10 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/43] | Title | German: | MITTEL ZUR PRÄVENTION/BEHANDLUNG VON THROMBOEMBOLIE FÜR THROMBOEMBOLIEPATIENTEN MIT SCHWERER NIERENFUNKTIONSSTÖRUNG | [2014/43] | English: | THROMBOEMBOLISM PREVENTIVE/THERAPEUTIC AGENT FOR THROMBOEMBOLISM PATIENTS HAVING SEVERE RENAL DYSFUNCTION | [2014/43] | French: | AGENT PRÉVENTIF/THÉRAPEUTIQUE D'UNE THROMBOEMBOLIE DESTINÉ À DES PATIENTS SOUFFRANT D'UNE THROMBOEMBOLIE ET PRÉSENTANT UN DYSFONCTIONNEMENT RÉNAL SÉVÈRE | [2014/43] | Entry into regional phase | 20.05.2014 | Translation filed | 20.05.2014 | National basic fee paid | 20.05.2014 | Search fee paid | 20.05.2014 | Designation fee(s) paid | 20.05.2014 | Examination fee paid | Examination procedure | 20.05.2014 | Examination requested [2014/43] | 19.11.2015 | Amendment by applicant (claims and/or description) | 01.07.2017 | Application deemed to be withdrawn, date of legal effect [2017/49] | 28.07.2017 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2017/49] | Fees paid | Renewal fee | 11.12.2014 | Renewal fee patent year 03 | 10.12.2015 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 31.12.2016 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XY] - THOMAS MAVRAKANAS ET AL, "The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism", PHARMACOLOGY AND THERAPEUTICS, vol. 130, no. 1, doi:10.1016/J.PHARMTHERA.2010.12.007, ISSN 0163-7258, (20101224), pages 46 - 58, (20101224), XP028148434 [X] 6 * page 52, column l, paragraph l - column r, paragraph 1 * [Y] 1-6 DOI: http://dx.doi.org/10.1016/j.pharmthera.2010.12.007 | [XY] - RUFF C T ET AL, "Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)", AMERICAN HEART JOURNAL, MOSBY- YEAR BOOK INC, US, vol. 160, no. 4, ISSN 0002-8703, (20101001), pages 635 - 641.e2, (20101001), XP027398415 [X] 6 * page 636 * [Y] 1-6 | International search | [Y]WO2010071164 (DAIICHI SANKYO CO LTD [JP], et al); | [Y] - RIDOUT, G. ET AL., "Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PK-PD model.", JOURNAL OF CLINICAL PHARMACOLOGY, (200909), vol. 49, no. 9, page 1124, XP008173592 | [Y] - "Lixiana (R) Tablets 15mg, Lixiana (R) Tablets 30mg Tenpu Bunsho", (201107), URL: http://www.info.pmda.go.jp/downfiles/ph/PDF/430574_3339002F1020102.pdf, XP008173546 | [Y] - "Lixiana Tablets 15mg, Lixiana Tablets 30mg Shinsa Hokokusho", (2011), pages 41 - 43, 66 TO 69, URL: http://www.info.pmda.go.jp/shinyaku/P201100072/430574000_22300AMX00547_A100_2.pdf, XP055150283 | by applicant | WO03000657 | WO03000680 | WO2010071164 | - THROMB. HAEMOST, (201009), vol. 104, no. 3, pages 633 - 41 | - AM. HEART J., (201010), vol. 160, no. 4, pages 635 - 41 | - CIRC. J., (2011), vol. 75, pages 1539 - 1547 |